Skip to main content
Premium Trial:

Request an Annual Quote

Johns Hopkins Selects Sapio's LIMS for Epigenetic Research

Premium

Sapio Sciences said this week that the Epigenetics Center of the Institute for Basic Biomedical Sciences at Johns Hopkins University has licensed its Exemplar Laboratory Information Management System and Electronic Lab Notebook software.

The center will use the Exemplar platform to manage lab samples and to handle Illumina HiSeq and Illumina Infinium platform workflows, Sapio said.

The Johns Hopkins center explores the epigenetic basis of normal development and disease and its researchers are working on several genomics, biostatistical, and biochemical methods for that purpose.

Baltimore, Md.-based Sapio said the researchers chose Exemplar because of its ability to manage data from multiple domains and to implement workflows and processes quickly.

Exemplar combines lab information management and electronic lab notebook capabilities, cheminformatics, and data-management tools in a single framework.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.